- United States
- /
- Software
- /
- NYSE:PATH
UiPath (PATH) Launches Maestro Flow, Is The Upside Already Priced In?
UiPath (PATH) has drawn fresh attention after launching Maestro Flow, a developer-focused orchestration canvas that brings AI agents, robots, APIs, documents, and people into a single governed workflow.
See our latest analysis for UiPath.
For context, UiPath shares trade at US$15.78, with a 30-day share price return of 29.77% and a 90-day return of 49.29%, while the 1-year total shareholder return is 43.98% following a much weaker 5-year total shareholder return of 75.69%.
If the Maestro Flow launch has you thinking about where automation could head next, it may be worth scanning other opportunities in AI and robotics through the 38 robotics and automation stocks.
After a sharp rebound and the Maestro Flow launch, the question for UiPath now is whether most of the easy gains are already behind the stock or if the current price still leaves meaningful upside on the table as valuation checks suggest.
Most Popular Narrative: 18.5% Overvalued
UiPath’s most followed narrative points to a fair value of $13.31, which sits below the recent $15.78 close and frames Maestro Flow against a richer valuation backdrop.
UiPath's focus on accelerating innovation across the agentic automation road map is expected to grow deeper customer relationships and strategic partnerships, likely driving future revenue growth. Increased adoption of UiPath's platform among existing customers, supported by strategic changes in the go-to-market structure, is aimed at enhancing customer engagement and boosting ARR growth.
If you want to see what sits behind that fair value, pay close attention to how revenue, margins and future earnings multiples are woven together in this narrative.
Result: Fair Value of $13.31 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, UiPath still faces risks that could unsettle this narrative, including slower net new ARR from delayed deals and ongoing FX and SaaS transition headwinds that are weighing on reported growth.
Find out about the key risks to this UiPath narrative.
Another View On UiPath Valuation
The consensus narrative frames UiPath as about 18.5% overvalued at $15.78 versus a $13.31 analyst fair value. Yet on earnings multiples, the picture is different. UiPath trades on a P/E of 25x, below peers at 38.4x and below an estimated fair ratio of 27.3x, which points to a potential valuation cushion rather than excess heat. Which signal do you treat as more important?
For a closer look at how this earnings based view stacks up against peers and where the fair ratio could pull the P/E over time, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If the mixed signals on UiPath have you unsure, do not wait for a consensus to form. Check the underlying data for yourself and weigh it against the 3 key rewards
Looking for more investment ideas beyond UiPath?
If UiPath has sharpened your interest in automation and AI, do not stop here. Use fresh data driven ideas to stress test and broaden your watchlist today.
- Target resilient potential by scanning 78 resilient stocks with low risk scores that may help steady your portfolio when individual stocks move sharply.
- Hunt for quality at a reasonable price with the 52 high quality undervalued stocks that filters for fundamentals instead of hype.
- Spot tomorrow's potential standouts early using the screener containing 20 high quality undiscovered gems before wider attention pushes valuations higher.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.
There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.
Market might be getting a little ahead of itself here.
About NYSE:PATH
UiPath
Provides an automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally.
Flawless balance sheet and undervalued.